1. Unit for Genomics in Myeloma, Institut Universitaire du Cancer de Toulouse–Oncopole, University Hospital, Toulouse, France;
2. Centre de Recherche en Cancérologie de Toulouse, INSERM U1037, Toulouse, France;
3. Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA; and
4. VA Boston Healthcare System, Boston, MA